CRISPR-Based Therapy Analytical Development on September 16-18, 2025 in Boston, United States

Welcome to the 3rd CRISPR-Based Therapy Analytical Development Summit

Spearheading Regulatory Compliance of Genome Editing Therapies

The 3rd CRISPR-Based Therapy Analytical Development Summit returns to Boston this September as the only industry-led meeting dedicated exclusively to analytical development for CRISPR-based therapeutics. As the race to the clinic accelerates, developers must deliver robust, regulatory-ready analytical packages to secure IND approval and demonstrate safety, efficacy, and product integrity to both regulators and investors.

With the FDA easing platform designation requirements and clinical milestones being reached across the field, from Beam Therapeutics’s proof-of-concept data to Arbor Biotherapeutics’ dual designations, analytical development has become a critical checkpoint. This summit unites analytical, QC, and regulatory leaders to explore cutting-edge tools for off-target detection, and to guide RNA validation, delivery analytics, and potency assay development.

Join experts from Beam, Mammoth, Excision, and KSQ Therapeutics to benchmark your strategy, gain actionable insights, and ensure your CRISPR programs are ready for regulatory progress and clinical success.

URLs:

Tickets: https://go.evvnt.com/3106017-2?pid=10008

Brochure: https://go.evvnt.com/3106017-3?pid=10008

Time: 9:00 AM - 5:00 PM

Prices:

Drug Developer Pricing - Conference + Workshop Day: USD 4197.00,

Drug Developer Pricing - Conference Only: USD 2999.00,

Academic and Small Biotech Pricing - Conference + Workshop Day: USD 3597.00,

Academic and Small Biotech Pricing - Conference Only: USD 2599.00,

Solution Provider Pricing - Conference + Workshop Day: USD 5097.00,

Solution Provider Pricing - Conference Only: USD 3699.00

Speakers: Abhinav Adhikari, Senior Scientist, Epic Bio, Carl Co, Senior Director - Analytical Sciences, Arbor Biotechnologies, Cindy Liu, Associate Director - Analytical Development and Molecular Group Lead, Prime Medicine, Eric Anderson, Director, Vor Biopharma, Howard Wu, Co-Founder and Chief Scientific Officer, Full Circle Therapeutics, Hugh Gannon, Associate Director, KSQ Therapeutics, Inc., Isabelle Gusev, Principal Scientist and Group Leader - Analytical Development, CMC, Tessera Therapeutics, Kai-Yuan Chen, Director - Computational Genomics and Data Science, Scribe Therapeutics, Maggie Bobbin, Director, Mammoth Biosciences, Matthew Laurie, Scientist, Bristol Myers Squibb, TJ Cradick, Chief Technology Officer, HuidaGene Therapeutics, Violetta Medik, Associate Director - Analytical Development, KSQ Therapeutics, Inc., Wenwen Huo, Principal Scientist and Senior Computational Biologist, Excision BioTherapeutics Inc., Xiaoya Sun, Analytical Development and Cell Therapy Scientist, Takeda Pharmaceutical, Yuqing Chang, Director, Beam Therapeutics Inc., Zack Zhang, Director, Beam Therapeutics Inc.